Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US8071568B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 28, 2007 |
| Grant date | Dec 6, 2011 |
| Priority date | — |
| Expiry date | Jun 24, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention. (I)
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.